X
<

Roche's Drugs, Trials, and FDA Approvals after 1H17

PART:
1 2 3 4 5 6 7 8 9 10 11
Part 8
Roche's Drugs, Trials, and FDA Approvals after 1H17 PART 8 OF 11

How Roche’s HER2 Franchise Is Positioned after 1H17

Herceptin revenue trends

In the first half of 2017, Roche’s (RHHBY) Herceptin reported revenues of CHF1 3.5 billion, which is a 3.0% rise on a YoY (year-over-year) basis. In that period in the US, European, and Japanese markets, Herceptin generated revenues of CHF 1.4 billion, CHF 1.0 billion, and CHF 143.0 million, respectively.

In 2Q17, Herceptin generated revenues of CHF 1.8 billion, which reflected a ~5.0% rise on a YoY basis and a 2.0% rise on a QoQ (quarter-over-quarter) basis.

Herceptin (trastuzumab) is used for the treatment of individuals with HER2 (human epidermal growth factor receptor 2) overexpressing breast cancer and HER2 overexpressing metastatic gastroesophageal junction adenocarcinoma.

How Roche’s HER2 Franchise Is Positioned after 1H17

Interested in RHHBY? Don't miss the next report.

Receive e-mail alerts for new research on RHHBY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Perjeta revenue trends

In the first half of 2017, Perjeta generated revenues of CHF 1.1 billion, which reflected a 17.0% rise on a YoY basis. In that period in the US, European, and Japanese markets, Perjeta generated revenues of CHF 507.0 million, CHF 366.0 million, and CHF 56 million, respectively.

In 2Q17, Perjeta generated revenues of CHF 541.0 million, which reflected a ~16.0% rise on a YoY basis and a ~3.0% rise on a QoQ basis.

Perjecta (pertuzumab) is used in combination with Herceptin and docetaxel for the treatment of HER2 positive metastatic breast cancer who did not previously receive chemotherapy for metastatic disease.

Kadcyla revenue trends

In the first half of 2017, Kadcyla reported revenues of CHF 443.0 million, which is a 9.0% rise on a YoY basis. In that period in the US, European, and Japanese markets, Kadcyla generated revenues of CHF 177.0 million, CHF 170.0 million, and CHF 33.0 million, respectively.

In 2Q17, Kadcyla generated revenues of CHF 211.0 million, which reflected a ~2.0% rise on a YoY basis and a ~5.0% fall on a QoQ basis.

Kadcyla is indicated for the treatment of HER2 positive metastatic breast cancer patients who have received prior treatment with trastuzumab and taxane in combination or separately.

Roche’s peers in the oncology drugs market include Celgene (CELG), Novartis (NVS), Pfizer (PFE), Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, and others. The growth in sales of Roche’s HER2 franchise could boost the share price of the Vanguard FTSE All-World ex-US ETF (VEU). Roche makes up ~0.73% of VEU’s total portfolio holdings.

  1. Swiss franc
X

Please select a profession that best describes you: